Home » Stocks » TPTX

Turning Point Therapeutics, Inc. (TPTX)

Stock Price: $129.52 USD -3.48 (-2.62%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 6.24B
Revenue (ttm) 25.00M
Net Income (ttm) -130.88M
Shares Out 42.19M
EPS (ttm) -3.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $129.52
Previous Close $133.00
Change ($) -3.48
Change (%) -2.62%
Day's Open 134.40
Day's Range 127.16 - 135.81
Day's Volume 273,682
52-Week Range 32.02 - 136.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 1 week ago

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China

Seeking Alpha - 3 weeks ago

TPTX has demonstrated solid competitive data for its lead asset. The company, after two rounds of dilution, is heavy with cash.

GlobeNewsWire - 1 month ago

Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Planned for Presentation at Upcoming World Conference on Lung Cancer Updated Data from TRI...

Insider Monkey - 1 month ago

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Other stocks mentioned: INSM, AUPH, CYTK, NEO
GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 2 months ago

Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...

GlobeNewsWire - 3 months ago

Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib Two Additional Abstracts Selected for Poster Presentations of Preclinical D...

GlobeNewsWire - 3 months ago

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers o...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers o...

GlobeNewsWire - 4 months ago

Preeminent Leaders in Cancer Signaling Pathways and Dysregulated Protein Kinases to Advise Company’s Early Pipeline Development Preeminent Leaders in Cancer Signaling Pathways and Dysregulated...

GlobeNewsWire - 4 months ago

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

Zacks Investment Research - 5 months ago

Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

Zacks Investment Research - 5 months ago

Turning Point Therapeutics (TPTX) delivered earnings and revenue surprises of 14.58% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead f...

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

GlobeNewsWire - 5 months ago

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

GlobeNewsWire - 6 months ago

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

The Motley Fool - 6 months ago

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.

GlobeNewsWire - 6 months ago

Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations ...

GlobeNewsWire - 7 months ago

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...

Benzinga - 8 months ago

Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday.

Seeking Alpha - 8 months ago

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Turning Point Therapeutics

Zacks Investment Research - 9 months ago

Turning Point Therapeutics (TPTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 11 months ago

SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

GlobeNewsWire - 11 months ago

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

ETF Trends - 1 year ago

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...

Other stocks mentioned: BYND, CRTX, IGMS, INMD, KRTX, NXTC, PLMR, SWAV
The Motley Fool - 1 year ago

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, APRE, BNTX, GKOS, INMD, KRTX, NXTC, PLMR, RAPT
Zacks Investment Research - 1 year ago

This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

Other stocks mentioned: BYND, KRTX, SILK, ZM
CNBC Television - 1 year ago

Turning Point Therapeutics CEO on the company's successful IPO

Dr. Athena Countouriotis, CEO of Turning Point Therapeutics, joins "Squawk Box" to discuss the succes of the company's IPO and what she expects going forward.

Zacks Investment Research - 1 year ago

Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today annou...

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today annou...

Seeking Alpha - 1 year ago

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2019 Results - Earnings Call Transcript

CNBC Television - 1 year ago

How Turning Point Therapeutics became a 2019 IPO standout

Turning Point Therapeutics is one of the 2019's IPO's that has been performing better than its cohorts, jumping 23% since its IPO.

About TPTX

Turning Point Therapeutics, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced s... [Read more...]

Industry
Biotechnology
IPO Date
Apr 17, 2019
CEO
Dr. Athena Maria Countouriotis
Employees
130
Stock Exchange
NASDAQ
Ticker Symbol
TPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for TPTX stock is "Strong Buy." The 12-month stock price forecast is 147.40, which is an increase of 13.80% from the latest price.

Price Target
$147.40
(13.80% upside)
Analyst Consensus: Strong Buy